The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Radioimmunotherapy of human tumours
Open accessAbstract
The eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Such radioimmunotherapy (RIT) permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering and radiochemistry in the past decade have markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,484
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Radiobiology for the Radiologist
Fry, R. J. M., & Hall, E. J. (1995) · Radiation Research · doi:10.2307/3579017 · Cited by 1,337
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
Self-citationCD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 584
Self-citation
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Targeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Metadata
- Authors
- Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W.
- Venue
- Nature Reviews Cancer
- Published
- 2015-05-22
- Volume
- 15
- Issue
- 6
- Pages
- 347-360
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1533229981
- Cited by
- 537
- References
- 110
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radioimmunotherapy of human tumours. https://app.cochat.ai/papers/10.1038/nrc3925
- The paper
- Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015). Radioimmunotherapy of human tumours. Nature Reviews Cancer. https://doi.org/10.1038/nrc3925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.